Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

New Alliance Capital

Founders Liefeng Qu

Overview

Investments

Unlock datapoints

Portfolio analytics

Team

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.

Need help with fundraising?

We offer an assisted fundraising option for startups

Learn more
Total investments 61
Average round size
info
The average size of a deal this fund participated in
$37M
Portfolio companies 49
Rounds per year 3.81
Lead investments 4
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.20
Exits 4
Key employees 3
Stages of investment
Early Stage Venture

Areas of investment

  • Health Care
  • Biotechnology
  • Manufacturing
  • Medical
  • Pharmaceutical
Summary

New Alliance Capital is the famous VC, which was founded in 2008. The main department of described VC is located in the Shanghai. The venture was found in Asia in China.

We can highlight the next thriving fund investment areas, such as Medical Device, Enterprise. The fund has no exact preference in some founders of portfolio startups. If startup sums 3 or 4 of the founder, the chance for it to be financed is low. For fund there is a match between the country of its foundation and the country of its the most frequent investments - China. Moreover, a startup needs to be at the age of 6-10 years to get the investment from the fund. Among the various public portfolio startups of the fund, we may underline Sight Diagnostics, Wuhan Zebra Express, ShopEx

This New Alliance Capital works on 18 percentage points less the average amount of lead investments comparing to the other organizations. The fund is constantly included in 2-6 deals per year. Deals in the range of 50 - 100 millions dollars are the general things for fund. The high activity for fund was in 2017. Despite it in 2019 the fund had an activity. The increased amount of exits for fund were in 2018. When the investment is from New Alliance Capital the average startup value is 500 millions - 1 billion dollars. Considering the real fund results, this VC is 9 percentage points less often commits exit comparing to other organizations.

The fund was created by Liefeng Qu. We also calculated 3 valuable employees in our database.

The typical case for the fund is to invest in rounds with 5-6 participants. Despite the New Alliance Capital, startups are often financed by Sequoia Capital China, Qiming Venture Partners, OurCrowd. The meaningful sponsors for the fund in investment in the same round are Shenzhen Capital Group, Tranquility Capital, Sequoia Capital China. In the next rounds fund is usually obtained by QJY Capital, Tranquility Capital, Steven Esrick.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of New Alliance Capital:
Typical Co-investors
New Alliance Capital is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after New Alliance Capital:
There are no funds here. If we find new data, we will add it here.

Funds with similar focus

Funds from China
Funds with similar focus located in China:
Funds with the same geo focus
Funds with similar geography of portfolio companies:
Funds doing lead investments
Funds with similar focus acting as lead investors:

Look at other 50 related and similar funds Collapse list
Fund NameLocation
Doral Energy-Tech Ventures Israel, Ramat Gan, Tel Aviv
Exponentially I Mobility India, Maharashtra, Mumbai
Grandbridge -
Green Dot Capital Central, Central Region, Singapore
HAT Sicaf SpA Italy, Lombardia, Milano
IRDI SORIDEC Gestion -
Juhe Touzi Anhui, China, Hefei
Lendingkart Ahmedabad, Gujarat, India
Napier Park Financial Partners New York, New York, United States
Navus Ventures Netherlands, South Holland, The Netherlands
Newton Press Japan, Tokyo
Polish Agency for Enterprise Development Mazowieckie, Poland, Warszawa
Rock Central Detroit, Michigan, United States
Toyota Industries Corp Awaji, Hyogo Prefecture, Japan
U.S. Army Medical Research & Development Command Louisiana, Maryland, United States
Valid S.A Brazil, São Paulo, Sao Paulo
Weingart Foundation California, Los Angeles, United States
Ysios Capital Barcelona, Catalonia, Spain

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Arnatar Therapeutics

$50M08 Apr 2024 San Diego, California, United States

Elite Technology

Analytics
Chemical Engineering
Product Research
$15M05 Jan 2024 Dalian Shi, Liaoning, China

LYNK Pharmaceuticals

Biotechnology
Health Care
Pharmaceutical
$18M21 Sep 2023 Hangzhou, Zhejiang, China

Xbotspace

Artificial Intelligence
08 Aug 2023 Xuhui, Shanghai, China

Eccogene

Health Care
$27M12 Jun 2023 Shanghai, China

Lips Semiconductor

Automotive
Electronics
Industrial
Manufacturing
Semiconductor
$15M17 Mar 2023 Wuxi, Anhui, China

GenScript ProBio

Biopharma
Medical
Pharmaceutical
$220M18 Jan 2023 Nanjing, Jiangsu, China

Core Medical Technology

Manufacturing
Medical
Medical Device
30 Dec 2022 Shenzhen, Guangdong, China

NeuroXess

Health Care
Health Diagnostics
Medical
28 Dec 2022 Huangpu, Shanghai, China
News
Lynk Pharmaceuticals Closes $50M Series B Financing

– Lynk Pharmaceuticals is a Hangzhou, China-based pharmaceutical R&D company.
– The company completed Series B financing of $50m.
– The round was led by Lilly Asia Ventures (LAV) with participation from New Alliance Capital and Hangzhou HEDA Biological Medicine Venture Capital Partnership (L.L.P.) and its original shareholders Legend Capital and Med-Fine Capital.
– The new investment will be used to conduct Phase I and II clinical trials for multiple programs in the R&D pipeline, expand international business, strengthen international collaborations with companies and support preclinical development of new projects.

Tavotek Biotherapeutics Snares $20M in Series A

– Tavotek Biotherapeutics from Lower Gwynedd, Pennsylvania, has raised over $20M in financing in the preceding two months.
YuanBio Venture Capital led the A1 finance round followed by Oriza Holdings, Ming BioVentures, and New Alliance Capital.
– Series A2 financing was jointly invested by GF Xinde, CTS Capital, and Lanhu Capital.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent New Alliance Capital?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!
Total investments 61
Average round size 37M
Rounds per year 3.81
Peak activity year 2021
Lead investments 4
Follow on index 0.20
Exits 4
Group Appearance index 0.84

Latest deals

CompanyIndustryRound SizeDateInvestorsLocation

Arnatar Therapeutics

$50M08 Apr 2024 San Diego, California, United States

Elite Technology

Analytics
Chemical Engineering
Product Research
$15M05 Jan 2024 Dalian Shi, Liaoning, China

LYNK Pharmaceuticals

Biotechnology
Health Care
Pharmaceutical
$18M21 Sep 2023 Hangzhou, Zhejiang, China

Xbotspace

Artificial Intelligence
08 Aug 2023 Xuhui, Shanghai, China

Eccogene

Health Care
$27M12 Jun 2023 Shanghai, China

Lips Semiconductor

Automotive
Electronics
Industrial
Manufacturing
Semiconductor
$15M17 Mar 2023 Wuxi, Anhui, China

GenScript ProBio

Biopharma
Medical
Pharmaceutical
$220M18 Jan 2023 Nanjing, Jiangsu, China

Core Medical Technology

Manufacturing
Medical
Medical Device
30 Dec 2022 Shenzhen, Guangdong, China

NeuroXess

Health Care
Health Diagnostics
Medical
28 Dec 2022 Huangpu, Shanghai, China
Crunchbase icon

Content report

The following text will be sent to our editors: